Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy

Definition and classification of cancer cachexia: an international consensus

(2011) Kenneth Fearon et al.   LANCET ONCOLOGY

Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia

(2010) Sílvia Busquets et al.   CLINICAL NUTRITION

Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”

(2010) M. Muscaritoli et al.   CLINICAL NUTRITION

Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia

(2010) Calum Gray et al.   CLINICAL NUTRITION

Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer

(2010) Richard J. E. Skipworth et al.   SUPPORTIVE CARE IN CANCER

A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands

(2009) Jessica R Lieffers et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Systemic administration of β2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses

(2006) James G Ryall et al.   BRITISH JOURNAL OF PHARMACOLOGY